Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of $0.10, $0.01 better than the analyst estimate of $0.09. Revenue for the quarter came in at $29.1 million versus the consensus estimate of $31.46 million.

“I am very proud of the way that the entire Catalyst team has quickly responded and adapted in these challenging and unprecedented times to ensure the safety of all employees, while still providing uninterrupted access to Firdapse® for LEMS patients and continuing our support with their healthcare providers, albeit remotely” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. “We entered 2020 with a very clear operational plan to drive the growth of the Firdapse franchise, advance our clinical development programs, including MuSK antibody positive Myasthenia Gravis, and secure our supply chain and safety stock of Firdapse. We have made progress against all of these objectives and our first quarter results reflect the solid execution of this plan.”

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.